Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Flinn, Ian W" or (type any "bookEditor journalEditor issueEditor" and editor="Flinn, Ian W")

Add to list
- Conference Paper
- C3
Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Nicole Lamanna, Marco Montilo, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone J Kuss, Constantine S Tam, Fritz Offner (UGent) , Francesc Bosch, Matthew S Davids, et al.

(2019) AMERICAN JOURNAL OF HEMATOLOGY. 94(suppl. 2). p.S20-S21
Add to list
- Journal Article
- A1
- open access
AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner (UGent) , Adriana Scheliga, Grzegorz S Nowakowski, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(14). p.1188-1199
Add to list
- Conference Paper
- C3
Characterization of the long-term efficacy and safety of duvelisib monotherapy in patients with relapsed/refractory CLL/SLL on treatment for > 2 years across 4 clinical studies

Ian W Flinn, Marco Montillo, Zsolt Nagy, Zoltan Gasztonyi, Matthew S Davids, Klaus Geissler, Jose J Rifon Roca, Leanne Berkhan, Fritz Offner (UGent) , NgocDiep Le, et al.

(2018) BLOOD. 132(suppl. 1).
Add to list
- Conference Paper
- C3
AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner (UGent) , Adriana Scheliga, Grzegorz S Nowakowski, et al.

(2018) BLOOD. 132(suppl. 1).
Add to list
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone J Kuss, Constantine S Tam, Zoltan Gasztonyi, et al.

(2018) BLOOD. 132(23). p.2446-2455
Add to list
- Conference Paper
- C3
Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone Jean Kuss, Constantine S Tam, Zoltan Gasztonyi, et al.

(2017) BLOOD. 130(suppl. 1).
Add to list
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Ian W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, Ann Janssens, Sebastian Grosicki, Wojciech Homenda, Lukas Smolej, Kazimierz Kuliczkowski, Michael Doubek, Natalia Domnikova, et al.

(2016) AMERICAN JOURNAL OF HEMATOLOGY. 91(9). p.900-906

Academic Bibliography

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

Characterization of the long-term efficacy and safety of duvelisib monotherapy in patients with relapsed/refractory CLL/SLL on treatment for > 2 years across 4 clinical studies

AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Contents

Support

Contact